Valuation: Amgen Inc.

Market Cap 224B 340,139B 201B 187B 170B 320B 21,478B 322B 2,251B 881B 11,064B 842B 824B 35,569B P/E 2026 *
26.5x
P/E 2027 * 23.6x
Enterprise Value 266B 403,151B 238B 222B 201B 380B 25,457B 382B 2,668B 1,044B 13,114B 998B 976B 42,158B EV / Sales 2026 *
6.82x
EV / Sales 2027 * 6.44x
Free-Float
99.77%
Yield 2026 *
2.42%
Yield 2027 * 2.55%
1 day+1.83%
1 week+3.48%
Current month-1.72%
1 month+10.63%
3 months+18.01%
6 months+29.01%
Current year+33.65%
1 week 21,510
Extreme 21510
22,460
1 month 19,910
Extreme 19910
22,940
Current year 15,920
Extreme 15920
23,810
1 year 12,320
Extreme 12320
23,810
3 years 7,000
Extreme 7000
23,810
5 years 1,312
Extreme 1312
23,810
10 years 273.67
Extreme 273.666666
23,810
Manager TitleAgeSince
Chief Executive Officer 63 01/05/2012
Director of Finance/CFO 62 13/05/2010
Chief Tech/Sci/R&D Officer 57 01/06/2023
Director TitleAgeSince
Chairman 63 01/01/2013
Director/Board Member 65 01/01/2012
Director/Board Member 71 01/01/2012
Change 5-day change 1-year change 3-year change Capi.($)
+1.83%+3.48% - - 224B
+0.28%+3.46%+41.89%+93.71% 1,051B
+0.88%+4.27%+38.28%+68.70% 630B
+1.68%+5.78%+21.96%+89.56% 489B
-0.10%+4.24%+69.15%+40.41% 359B
+0.61%+3.18%+24.05%+42.46% 344B
+0.72%+2.99%+14.29%+34.71% 272B
+0.23%+2.23%-5.91%+8.15% 246B
+0.65%+3.62%+43.93%+46.50% 224B
-0.49%+4.01%+28.38%+95.97% 187B
Average +0.63%+2.86%+30.67%+57.80% 422.63B
Weighted average by Cap. +0.64%+2.93%+34.07%+66.93%

Financials

2026 *2027 *
Net sales 38.97B 59,094B 34.92B 32.52B 29.5B 55.64B 3,732B 55.99B 391B 153B 1,922B 146B 143B 6,180B 40.37B 61,222B 36.18B 33.69B 30.56B 57.65B 3,866B 58.01B 405B 159B 1,991B 152B 148B 6,402B
Net income 8.53B 12,937B 7.65B 7.12B 6.46B 12.18B 817B 12.26B 85.6B 33.5B 421B 32.04B 31.33B 1,353B 9.39B 14,240B 8.42B 7.84B 7.11B 13.41B 899B 13.49B 94.22B 36.87B 463B 35.26B 34.49B 1,489B
Net Debt 41.55B 63,012B 37.24B 34.67B 31.46B 59.33B 3,979B 59.7B 417B 163B 2,050B 156B 153B 6,589B 35.9B 54,439B 32.17B 29.96B 27.18B 51.26B 3,438B 51.58B 360B 141B 1,771B 135B 132B 5,693B
Projected Income Statement - Annual - Amgen Inc.
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
09/10/26 ARS 22,280.00 +1.83% 401
08/10/26 ARS 21,880.00 -1.40% 741
07/10/26 ARS 22,190.00 +3.07% 1,131
06/10/26 ARS 21,530.00 0.00% 641
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Amgen Inc.
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
34
Last Close Price
417.57USD
Average target price
393.91USD
Spread / Average Target
-5.67%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Amgen Inc.